example look at pg it split at 101 opened at 51 2for 1split
Wait till you see the new numbers after GILD reports in July. Most analysts don't have Ambri in their models, but they'll use the quarter to update.
Look for GILD to put 80 cents on the wheel again and virtually guarantee a 2007 over $3.20 in earnings. A good quarter, a new product, continued growth - the analysts will be racing to move their price targets up. The people will follow, but you heard it hear first.
>Wait till you see the new numbers after GILD reports in > July. Most analysts don't have Ambri in their models, but > they'll use the quarter to update.
None of them do, because GILD refused to give guidance on Ambri. So the above is correct.
However, remember that Ambri is not a big part of GILDs pipeline yet. They are not expecting it to make a big impact this year. The market is only about 200,000 patients in the US, and Other than US (OUS) will not start till sometime in 2008.
There are other drugs in the GILD pipeline that will be coming in the latter part of this year, and first part of next. In the meantime, the HIV drugs continue to take market share. And the cancer drugs continue to be developed, along with off label uses for their existing patents.
Anybody who things Myogen was purchased JUST for Ambri is seriously delusional.
So GILD will go up post split, and it would continue to go up if the split didn't happen. Splits do not make any significant difference in the long run.
But its not going up as fast as you seem to think. Not unless there are surprises in the pipe.